Evaluation of Spinal Mobility Reeducation in Patients Treated for a Lumbar Spinal Stenosis After Epidural Infiltration (CLEMOB)

October 22, 2020 updated by: University Hospital, Bordeaux

Evaluation of Spinal Mobility Reeducation in Patients Treated for a Lumbar Spinal Stenosis After Epidural Infiltration. Randomized and Comparative Study: Kyphosis Reeducation Versus Spinal Mobility Reeducation

In actual practice the patients with mild or moderate lumbar spinal stenosis symptoms receive an epidural infiltration and participate in kyphosis reeducation in first intention. Yet the kyphosis reeducation did not show a real profit in the time compared with the natural evolution of the pathology. The study assume that the spinal mobility reeducation will reduce the incidence of pain recurrences compared with the classic kyphosis reeducation.

Study Overview

Status

Terminated

Detailed Description

The standard treatment of lumbar spinal stenosis is the lumbar canal recalibration surgery which presents co-morbidity factors and risks of post-operative complications. The non-invasive methods are a good alternative compared with the surgery : the patients medically treated present few damages and the results of the postponed surgery are equivalent to the immediate surgery. That is why a non-surgical treatment is proposed in first intention to the patients with mild or moderate symptoms : this treatment associates an epidural infiltration and a kyphosis reeducation.

Yet the kyphosis reeducation did not show a real profit in the time compared with the natural evolution of the pathology. The benefits of the infiltration are lost three months after this one in 80 % of the cases. A return to physical activity and a restored spinal mobility would improve the duration of the infiltration effect. The objective is then to compare the efficiency of a spinal mobility reeducation program versus a kyphosis reeducation program in patients with acquired and central lumbar spinal stenosis. It is a prospective, monocentric, randomized, superiority and parallel-group study :

  • group C (control group) : kyphosis reeducation + patient education + auto-reeducation at home,
  • group M (test group) : spinal mobility reeducation + patient education + auto-reeducation at home.

Study Type

Interventional

Enrollment (Actual)

23

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bordeaux, France, 33000
        • University Hospital of Bordeaux - Hospital Pellegrin

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age > 50 years,
  • central, acquired and multi-staged lumbar spinal stenosis,
  • pain since at least three months,
  • radicular pains higher than the lumbar pains,
  • walking distance < 1000 m,
  • oral consent.

Exclusion Criteria:

  • intercurrent pathology limiting the walking distance (arteriopathy, cardio-respiratory insufficiency, disabling arthrosis affecting the lower limbs...),
  • history of spinal surgery for lumbar spinal stenosis,
  • extended lumbar arthrodesis (equal to or greater than 2 levels),
  • monosegmental and degenerative spondylolisthesis,
  • foraminal stenosis,
  • motor deficit of the lower limbs or Cauda equina syndrome ("Cauda equina" syndrome (CES) is a serious neurologic condition in which damage to the cauda equina causes acute loss of function of the lumbar plexus, (nerve roots) of the spinal canal below the termination (conus medullaris) of the spinal cord),
  • bleeding disorders or allergies contraindicating the epidural infiltration.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Control group (C)
Kyphosis reeducation + patient education + auto-reeducation at home
  • kyphosis reeducation on Huber platform during 2 weeks,
  • patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),
  • flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),
  • exercises on cycle ergometer or walking on treadmill : to continue at home.
Other: Test group (M)
Spinal mobility reeducation + patient education + auto-reeducation at home.
  • spinal mobility reeducation on Huber platform during 2 weeks,
  • patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),
  • flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),
  • exercises on cycle ergometer or walking on treadmill : to continue at home.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
maximal walking distance
Time Frame: the 90 days visit
: ratio between the maximal walking distance at the 90 days visit and the maximal walking distance at the Day 4 in percent. Walking on a plane road, 70 m in length, without obstacle and with markings every 10 meters (total length : not more than 2 km).
the 90 days visit

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
evaluation of the lumbar pain
Time Frame: Day 0
evaluation of the lumbar pain: measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 0
evaluation of the lumbar pain
Time Frame: Day 4
evaluation of the lumbar pain: measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 4
evaluation of the lumbar pain
Time Frame: Day 30
evaluation of the lumbar pain: measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 30
evaluation of the lumbar pain
Time Frame: Day 90
evaluation of the lumbar pain: measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 90
evaluation of the lumbar pain
Time Frame: Day 365
evaluation of the lumbar pain: measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 365
evaluation of the radicular pain
Time Frame: Day 0
measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 0
evaluation of the radicular pain
Time Frame: Day 4
measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 4
evaluation of the radicular pain
Time Frame: Day 30
measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 30
evaluation of the radicular pain
Time Frame: Day 90
measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 90
evaluation of the radicular pain
Time Frame: Day 365
measured by a verbal analog scale 0-100 mm (0 : no pain, 100 : maximal pain),
Day 365
evaluation scales
Time Frame: Day 0
evaluation scales : score of Quebec (functional impotence)
Day 0
evaluation scales
Time Frame: Day 4
evaluation scales : score of Quebec (functional impotence)
Day 4
evaluation scales
Time Frame: Day 30
evaluation scales : score of Quebec (functional impotence)
Day 30
evaluation scales
Time Frame: Day 90
evaluation scales : score of Quebec (functional impotence)
Day 90
evaluation scales
Time Frame: Day 365
evaluation scales : score of Quebec (functional impotence)
Day 365
maximal walking distance
Time Frame: Day 0
maximal walking distance : on a defined road
Day 0
maximal walking distance
Time Frame: Day 4
maximal walking distance : on a defined road
Day 4
maximal walking distance
Time Frame: Day 30
maximal walking distance : on a defined road
Day 30
maximal walking distance
Time Frame: Day 90
maximal walking distance : on a defined road
Day 90
maximal walking distance
Time Frame: Day 365
maximal walking distance : on a defined road
Day 365
compliance with the auto-reeducation at home
Time Frame: Day 30
compliance with the auto-reeducation at home : questionnaire.
Day 30
compliance with the auto-reeducation at home
Time Frame: Day 90
compliance with the auto-reeducation at home : questionnaire.
Day 90
compliance with the auto-reeducation at home
Time Frame: Day 365
compliance with the auto-reeducation at home : questionnaire.
Day 365
Score of Japanese Orthopaedic Association (llumbar radiculopathy)
Time Frame: Day 4
Day 4
Score of Japanese Orthopaedic Association (llumbar radiculopathy)
Time Frame: Day 30
Day 30
Score of Japanese Orthopaedic Association (llumbar radiculopathy)
Time Frame: Day 90
Day 90
Score of Japanese Orthopaedic Association (llumbar radiculopathy)
Time Frame: Day 365
Day 365
score of "Douleur Neuropathique 4" (DN4 - neuropathy)
Time Frame: Day 4
Day 4
score of "Douleur Neuropathique 4" (DN4 - neuropathy)
Time Frame: Day 30
Day 30
score of "Douleur Neuropathique 4" (DN4 - neuropathy)
Time Frame: Day 90
Day 90
score of "Douleur Neuropathique 4" (DN4 - neuropathy)
Time Frame: Day 365
Day 365
score Medical Outcomes Study Short-Form General Health Survey 12 (health status)
Time Frame: Day 4
Day 4
score Medical Outcomes Study Short-Form General Health Survey 12 (health status)
Time Frame: Day 30
Day 30
score Medical Outcomes Study Short-Form General Health Survey 12 (health status)
Time Frame: Day 90
Day 90
score Medical Outcomes Study Short-Form General Health Survey 12 (health status)
Time Frame: Day 365
Day 365

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Mathieu DE-SÈZE, MD, service de médecine physique et de réadaptation, Centre Hospitalier Universitaire de Bordeaux,
  • Study Chair: Antoine BENARD, MD, USMR CHU Bordeaux

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 15, 2016

Primary Completion (Actual)

June 1, 2018

Study Completion (Actual)

June 1, 2018

Study Registration Dates

First Submitted

June 4, 2015

First Submitted That Met QC Criteria

November 18, 2015

First Posted (Estimate)

November 20, 2015

Study Record Updates

Last Update Posted (Actual)

October 26, 2020

Last Update Submitted That Met QC Criteria

October 22, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lumbar Spinal Stenosis

Clinical Trials on Control group (C)

3
Subscribe